Neurocrine v. Spruce Biosciences: CAH Patent Case Dismissed for Lack of Jurisdiction
Neurocrine Biosciences filed suit against Spruce Biosciences in the Delaware District Court alleging infringement of US11344557B2, a patent covering classic congenital adrenal hyperplasia therapy linked to its CRENESSITY (crinecerfont) product. Judge Wolson dismissed the case without prejudice after just 146 days — not on the merits, but for lack of subject matter jurisdiction.
Jurisdictional threshold kills CAH patent suit before merits are reached
On January 14, 2025, Neurocrine Biosciences, Inc. filed a patent infringement action in the Delaware District Court against Spruce Biosciences, Inc., asserting US11344557B2. The patent relates to crinecerfont-based treatment of classic congenital adrenal hyperplasia (CAH) — the same mechanism underlying Neurocrine’s commercially approved CRENESSITY product. The accused product is Spruce’s tildacerfont, a competing CRF1 receptor antagonist in development for CAH.
Rather than engaging on infringement or validity, Spruce moved to dismiss under ECF No. 18, arguing the court lacked subject matter jurisdiction. Judge Joshua D. Wolson granted that motion on June 9, 2025, ordering the case dismissed without prejudice. A dismissal without prejudice means the court made no finding on the underlying patent claims — Neurocrine retains the right to refile if it can establish a jurisdictional basis, such as a more concrete case or controversy.
The 146-day resolution is notably fast, consistent with a case that never advanced beyond threshold procedural challenges. The dismissal suggests Spruce successfully argued the dispute was not yet ripe — or that Neurocrine lacked standing at the time of filing, possibly because tildacerfont had not received FDA approval or caused a sufficiently concrete injury. The precise jurisdictional defect is not specified in the public termination record, leaving Neurocrine’s litigation strategy — and the enforceability window — open to reassessment.
Filing to Dismissed without Prejudice in 146 days
146 days — resolved before substantive patent merits were ever reached
Dismissed without prejudice: what the jurisdictional ruling means for both parties
Subject matter jurisdiction dismissal: no merits decided
A dismissal for lack of subject matter jurisdiction under Rule 12(b)(1) means the court never reached the question of whether infringement occurred. The court determined it lacked the constitutional or statutory authority to hear the dispute at this time — typically because no sufficiently ripe ‘case or controversy’ existed under Article III. The without-prejudice designation confirms no res judicata effect attaches.
Procedural — not a patent validity rulingNeurocrine retains the right to refile — but must cure the jurisdictional defect
Because the dismissal is without prejudice, Neurocrine Biosciences can reassert its infringement claims against Spruce’s tildacerfont if and when the jurisdictional threshold is met — for example, upon tildacerfont’s FDA approval or a more concrete threatened injury. No adverse finding was made on US11344557B2. The patent remains enforceable, and the litigation clock has not started on the merits.
Refile possible if jurisdiction establishedSpruce avoids early merits fight — but not indefinitely
Spruce Biosciences prevailed on procedural grounds, avoiding costly claim construction and discovery at this stage. However, a without-prejudice dismissal is not a permanent shield. If tildacerfont advances toward FDA approval or commercialisation, a concrete case or controversy will likely crystallise, potentially resurrecting Neurocrine’s infringement claims. Spruce should treat this as a reprieve, not a resolution.
Merits risk deferred, not eliminatedCAH therapy competition: patent risk follows pipeline progression
The CAH space is commercially consequential — CRENESSITY is the first approved CRF1 antagonist for classic CAH, and tildacerfont is its closest competitive threat. This dismissal signals that patent enforcement in pharmaceutical contexts can be timed to regulatory milestones. Companies developing competing therapies should track both pipeline progress and the patent holder’s litigation posture as approval approaches.
Regulatory milestone triggers litigation riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Neurocrine Biosciences, Inc. | Company | Biopharmaceutical company — holder of US11344557B2 covering CAH therapy (crinecerfont)Search in Eureka ↗ |
| Defendant | Spruce Biosciences, Inc. | Company | Clinical-stage biopharmaceutical company developing tildacerfont for congenital adrenal hyperplasiaSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Bindu Ann George Palapura | Attorney | Counsel for Spruce Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | David Ellis Moore | Attorney | Counsel for Spruce Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Emily Shingle | Attorney | Counsel for Spruce Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Jessica Ramsey | Attorney | Counsel for Spruce Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Jordan R. Jaffe | Attorney | Counsel for Spruce Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Wendy L. Devine | Attorney | Counsel for Spruce Biosciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing Spruce Biosciences, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Joshua D. Wolson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order — granting Spruce’s motion to dismiss without prejudice for lack of subject matter jurisdiction — is a threshold ruling with no bearing on the validity or infringement of US11344557B2. The ‘without prejudice’ qualifier is legally significant: it preserves Neurocrine’s ability to refile once a justiciable controversy matures. The order does not assess claim scope, obviousness, or whether tildacerfont falls within the patent’s claims. Both parties effectively return to their pre-suit positions, with the patent holder’s enforcement rights fully intact.
US11344557B2 — CRF1 receptor antagonist therapy for classic congenital adrenal hyperplasia
US11344557B2 (application no. US17/063592) covers compositions and/or methods relating to CRF1 receptor antagonist treatment of classic congenital adrenal hyperplasia. Crinecerfont — marketed by Neurocrine as CRENESSITY — is the first drug of this class to receive FDA approval for CAH, a rare endocrine disorder caused by impaired cortisol biosynthesis. The patent’s grant date and application lineage position it as a core asset in Neurocrine’s CAH franchise.
For the biopharmaceutical sector, US11344557B2 represents a blocking position in a therapeutically validated, commercially active disease area. Tildacerfont, Spruce’s development-stage candidate, targets the same CRF1 receptor mechanism, making claim scope and prosecution history central to any future freedom-to-operate analysis. Competitors in the CAH space — including those developing next-generation CRF1 antagonists or combination therapies — should monitor continuation applications and any inter partes review proceedings that may follow.
Should your CAH programme run an FTO against US11344557B2?
Any R&D or product team developing a CRF1 receptor antagonist for congenital adrenal hyperplasia — whether small molecule, peptide-based, or combination — should treat US11344557B2 as a primary clearance target. Neurocrine’s willingness to litigate at the earliest commercially plausible moment signals active enforcement intent. Waiting until IND or NDA stage to assess FTO exposure in this space carries material risk.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US11344557B2, surface related continuations and divisionals in Neurocrine’s portfolio, and flag prosecution history estoppel that may bound claim scope. For teams developing tildacerfont competitors or next-generation CAH therapies, Eureka’s prior art and landscape tools provide the analytical foundation needed before committing to clinical investment.
Run a freedom-to-operate analysis on US11344557B2 to assess your product’s exposure
Run FTO in Eureka →Similar CAH and rare endocrine disease patent disputes in Delaware District Court
Cases involving CRF1 receptor antagonist patents and rare endocrine therapy infringement actions litigated in the Delaware District Court.
What this case signals for the CAH biopharmaceutical IP landscape
A jurisdiction-first strategy from Spruce reset the litigation timetable — but Neurocrine’s patent position remains intact and ready to redeploy.
Jurisdiction timing is a legitimate defensive tool in pharma patent disputes
Spruce’s successful Rule 12(b)(1) motion illustrates that early-stage pharma defendants can challenge whether a live controversy exists before a competitor’s product is approved. Companies developing pipeline drugs should assess whether a plaintiff can establish standing and ripeness at the time of filing — especially when the accused product lacks FDA clearance.
US11344557B2 remains a live enforcement threat for tildacerfont’s approval pathway
The dismissal without prejudice leaves Neurocrine’s CAH patent fully intact and reusable. Any entity in the CRF1 antagonist space — particularly those approaching NDA or BLA filing — should treat this patent as an active risk asset. A second action is plausible the moment jurisdictional prerequisites are satisfied.
Neurocrine v Spruce — key questions answered
Judge Wolson granted Spruce’s motion to dismiss on June 9, 2025 for lack of subject matter jurisdiction. The court did not reach the merits of the infringement claims. The without-prejudice designation means Neurocrine retains the right to refile if and when a justiciable case or controversy arises, such as upon tildacerfont’s FDA approval.
Neurocrine asserted US11344557B2 (application no. US17/063592), a patent covering CRF1 receptor antagonist therapy for classic congenital adrenal hyperplasia. This patent is associated with Neurocrine’s FDA-approved CRENESSITY (crinecerfont) product. Spruce’s accused product is tildacerfont, a competing CRF1 antagonist in clinical development.
It means no court assessed whether the patent was valid or infringed. US11344557B2 remains fully enforceable. The dismissal only reflects that the court found no live, justiciable controversy at the time of filing — not that the patent is weak or that Spruce’s tildacerfont is non-infringing. Neurocrine’s enforcement position is unchanged.
Yes. A without-prejudice dismissal imposes no res judicata bar. Neurocrine can refile once the jurisdictional defect is cured — most likely when tildacerfont advances to a regulatory milestone that creates a concrete threatened injury, such as an NDA filing or FDA approval. The patent’s remaining term governs the enforceability window.
Tildacerfont is Spruce Biosciences’ investigational CRF1 receptor antagonist being developed for congenital adrenal hyperplasia. It targets the same biological mechanism as crinecerfont, the active ingredient in Neurocrine’s CRENESSITY. Neurocrine alleges that tildacerfont falls within the claims of US11344557B2, though the court in this case never ruled on whether infringement actually occurred.
PatSnap Eureka searches patents and litigation data to answer instantly.